Bristol Myers Squibb Company (BMY) sees a rise in holdings from several major institutions, including Independent Franchise Partners LLP, Prudential PLC, Glenmede Investment Management LP, and Quadrature Capital Ltd, adding to a general trend of increased interest in the company. At the same time, other financial institutions such as Dodge & Cox, KLCM Advisors Inc., and Martingale Asset Management LP are reducing their positions in BMY. The company's recent performance comes after overcoming
Eliquis patent expiry and experiencing share price volatility. BMY has demonstrated a promising growth portfolio driving
revenue and earnings reset. Regulatory approval came through for
Sotyktu for psoriatic arthritis, while
Milvexian data are anticipated. The company also scored a win with its triple-negative breast cancer phase III trial. A
new pill that delays myeloma progression has been successful in late-stage trials. An assessment of BMY's valuation considers recent share price momentum and 2024 results. The company's
deep pipeline is seen as a key to future growth. These developments are shaping the investment narrative for Bristol Myers Squibb, with various analysts confident of its outlook.
Bristol-Myers Squibb BMY News Analytics from Wed, 01 Oct 2025 07:00:00 GMT to Sat, 14 Mar 2026 11:20:55 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -4
